Dr Reddy’s Reports 36% Dip in Q2 PAT, Calls Margin Cap Positive
Dr Reddy’s said the cap on trade margins for 137 anti-cancer drugs is expected to increase patient access to medicines.
Hyderabad-based Dr Reddy’s Labs described the recent cap on trade margins for 137 anti-cancer drugs by the National Pharmaceutical Pricing Authority, the drug-pricing watchdog, as a positive move. The company said the decision is expected to improve patients’ access to lifesaving medicines.